Analyst Expectations For Celldex Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Celldex Therapeutics (NASDAQ:CLDX) has been evaluated by 11 analysts over the past three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $64.64, down from $66.00. Analysts have maintained or announced ratings, with price targets ranging from $37.00 to $80.00. The company has shown significant revenue growth and strong financial health, despite a negative net margin and ROE.
October 28, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Celldex Therapeutics has received mixed analyst ratings, with a current average price target of $64.64, slightly down from $66.00. The company shows strong revenue growth and financial health, despite negative net margins and ROE.
The mixed analyst ratings indicate a neutral short-term impact on the stock price. The slight decrease in the average price target suggests some caution, but the strong revenue growth and financial health provide a positive outlook. The company's financial metrics, despite negative net margins and ROE, show efficient cost management and asset use.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100